Has Mounjaro Been Tested — and What Did the Evidence Find?

Step 1: How tirzepatide was developed and what the early studies set out to prove

The story of Mounjaro's development begins with the observation that two gut hormones, GLP-1 and GIP, both play a role in appetite regulation and blood-sugar control. Researchers at Eli Lilly developed tirzepatide as a dual agonist that activates both receptor pathways simultaneously. Early-phase studies tested safety, tolerability and dose-finding in progressively larger groups before the medicine moved into the large phase-3 trials that would determine whether it could actually be licensed. If you want to understand what tirzepatide physically contains and how its mechanism works at a molecular level, our guide to tirzepatide's composition covers that ground in detail. This staged development process is standard for any medicine seeking regulatory approval, and Mounjaro cleared every stage before appearing on a UK pharmacy shelf.

The development history itself is worth reading. Our page on the discovery of tirzepatide explains how the dual-agonist concept emerged from decades of incremental hormone research.

Step 2: What the SURMOUNT phase-3 trials actually measured, and found

The SURMOUNT programme is the backbone of Mounjaro's evidence. SURMOUNT-1 is the pivotal trial for weight management: 2,539 adults with obesity or overweight plus at least one weight-related condition (but without type 2 diabetes) were randomised to one of three tirzepatide doses or placebo and followed for 72 weeks. At the 15mg maintenance dose, average weight reduction was around 20–21% of starting body weight. The trial was published in the New England Journal of Medicine and formed a central part of the evidence reviewed by NICE and the MHRA. Those findings led NICE to recommend tirzepatide for NHS use under its technology appraisal TA1026, published in December 2024. SURMOUNT-2 extended the evidence to adults with type 2 diabetes; further arms of the programme examined cardiovascular and other outcomes. The trials measured weight, waist circumference, blood pressure, blood lipids and patient-reported quality of life, not weight alone.

One reason the results attracted attention is their consistency: meaningful reductions appeared across age groups, BMI ranges and ethnic backgrounds within the trial populations. The data also informed the prescribing information you will find on the Mounjaro SmPC on the eMC, which is the document your prescriber and pharmacist refer to for dosing, contraindications and storage guidance.

Step 3: How Mounjaro compares with the other licensed option, and what the head-to-head showed

For anyone trying to put Mounjaro's evidence in context, the SURMOUNT-5 trial is the most direct reference point available. It compared tirzepatide head-to-head with semaglutide 2.4mg (Wegovy) in 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. That trial was published in the New England Journal of Medicine in 2025 and the results were noted in NICE's committee discussions. Semaglutide 2.4mg itself had produced around 15% average reduction in its own STEP 1 trial, so neither result is modest. The clinical question of which medicine suits a given individual involves their medical history, other medicines they take, and personal preference, something our tirzepatide overview explores further. Getting into the cost picture alongside the evidence is something many people do when weighing their options; our Mounjaro price guide explains what private treatment typically involves financially. For a broader sense of the weight-loss medicines licensed in the UK right now, the weight-loss treatment overview pulls those options together.

Step 4: What happens after a medicine is licensed, ongoing monitoring

Regulatory approval is not the end of testing. Mounjaro carries a Black Triangle (▼) designation in the UK, which means the MHRA requires additional monitoring beyond what applies to longer-established medicines. Healthcare professionals and patients can report any suspected side effects directly through the MHRA Yellow Card scheme. In practice this means the real-world safety profile continues to be built as more people use the medicine. Common side effects identified across the trials were largely gastrointestinal: nausea, loose stools, constipation and indigestion were the most frequently reported, typically most noticeable when starting or moving to a higher dose, then easing over days or weeks. The January 2026 MHRA Drug Safety Update drew attention to acute pancreatitis as an infrequent but serious risk across GLP-1 medicines generally: severe, persistent abdominal pain that radiates to the back warrants prompt medical attention. Some people also notice fatigue in the early weeks; our page on tiredness while taking Mounjaro sets out what is typically behind that. The MHRA also requires blood tests to be considered before and during treatment in certain cases; the Mounjaro blood test page explains when your prescriber may ask for one. None of this replaces reading your patient information leaflet in full, which is the document tailored to the specific pen you have been prescribed.

If you are ready to find out whether treatment is clinically suitable for you, a named prescriber at our GPhC-registered pharmacy will review your consultation the same day. Start your free consultation to take that first step.